We specialize in the development and in-licensing of combinations of off-patent active ingredients in a single pill, as well as in the marketing of innovative drugs. Our portfolio includes both proprietary products and strategic partnerships. We focus on cardiovascular diseases.
APONTIS PHARMA enjoys a strong reputation among prescribers and funders in Germany – all thanks to well-established and sustainable access to approx. 23,500 physicians in private practice.
Because of its holistic growth strategy, APONTIS PHARMA can add further drugs to its portfolio. Within this context, we offer cooperations in the form of co-promotion, fee-for-call, acquisition of established brands, and in-licensing and out-licensing both in existing product areas and for new indications.
We stand for exchange and connections. For the benefit of our patients. Day after day.
Our current product collaborations on the German market at a glance
Ramipril / Amlodipin
Rosuvastatin / Ezetimib
Our PartnershipsAPONTIS PHARMA – the name is new, the high-quality standard has been the same for decades. We are an established pharmaceutical company, active in the promotion and marketing of innovative, ethical pharmaceuticals for general practitioners, selected medical specialists and primary care providers. With a strong sales force, APONTIS PHARMA is the partner of choice for a variety of large pharmaceutical companies. Long-standing and trusting partnerships are the key to mutual success.
APONTIS PHARMA's strategic partnerships include joint development and commercialization agreements with a wide range of small to large pharmaceutical (biotech) companies. APONTIS PHARMA is dedicated to expanding its pipeline and product portfolio with innovative products and established brands that benefit patients with serious diseases. Here, the clear focus is on marketing and promotion in the primary care physician and specialist segments.
Our focus on the futureAt least 20 market-launched Single Pills by 2026.
As the market-leading Single Pill company, we aim to ensure the therapeutic success of patients with highly-effective medicines, and we endeavor to reduce costs for insurers to a minimum. We have many years of expertise in the so-called modern civilization diseases.
Since 2013, we have launched eleven Single Pills on the market, all of which have been very successful. Our medicines are now used to treat hundreds of thousands of patients. Overall, we aim to expand our portfolio from the current eleven marketed Single Pills to at least 20 in 2026. As such, the number of potential patients for APONTIS PHARMA would triple from the current level of around 3 million to 9 million.